NCT03041259: An overdue trial by Reven Pharmaceuticals, Inc.
This trial is overdue. It was due to report 1 year, 2 months ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT03041259 |
|---|---|
| Title | A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of Rejuveinix in Combination With Standard Interventional Therapy for Critical Limb Ischemia Patients |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 31, 2020 |
| Completion date | Jan. 31, 2022 |
| Required reporting date | Jan. 31, 2023, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
| Days late | 374 |